From a0b0548d54ee887be7037695126cc66d480a4624 Mon Sep 17 00:00:00 2001 From: GitHub Action Date: Mon, 16 Oct 2023 05:16:02 +0000 Subject: [PATCH 1/4] Updated studies --- src/data/studies/studies.json | 53 ++++++++++++++++++++--------------- 1 file changed, 31 insertions(+), 22 deletions(-) diff --git a/src/data/studies/studies.json b/src/data/studies/studies.json index d6802edf..b5d88772 100644 --- a/src/data/studies/studies.json +++ b/src/data/studies/studies.json @@ -98,24 +98,6 @@ "Consent Short": "phs000284.v2.p1.c1", "Subject Count": 1473 }, - { - "Accession": "phs000285.v3.p2", - "Cohort Abbreviation": "CARDIA", - "Name": "Coronary Artery Risk Development in Young Adults (CARDIA) Study - Cohort", - "Description": "CARDIA is a study examining the etiology and natural history of cardiovascular disease beginning in young adulthood. In 1985-1986, a cohort of 5115 healthy black and white men and women aged 18-30 years were selected to have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, and education (high school or less and more than high school) within each of four US Field Centers. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), and 2010-2011 (Year 25); the proportions of the surviving cohort that have returned for the seven follow-up examinations were 90%, 86%, 81%, 79%, 74%, 72%, and 72%, respectively. In addition to the follow-up examinations, participants are contacted regularly for the ascertainment of information on out-patient procedures and hospitalizations experienced between contacts. Within the past five years, 95% of the original surviving cohort has been contacted. While the specifics of each examination has differed somewhat, data have been collected on a variety of factors believed to be related to heart disease. These include conditions with clear links to heart disease such as blood pressure, cholesterol and other lipids. Data have also been collected on physical measurements such as weight and skinfold fat as well as lifestyle factors such as substance use (tobacco and alcohol), dietary and exercise patterns, behavioral and psychological variables, medical and family history, and other chemistries (e.g., insulin and glucose). In addition, subclinical atherosclerosis was measured via echocardiography during Years 5, 10, and 25, computed tomography during Years 15 and 20, and carotid ultrasound during Year 20. The CARDIA Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the \"Sub-studies\" box located on the right hand side of this top-level study page phs000285 CARDIA Cohort. phs000236 PAGE_CALiCo_CARDIA phs000309 GENEVA_CARDIA phs000399 GO-ESP HeartGO_CARDIA phs000613 CARDIA_CARe Study Weblinks: CARDIA Study Design: Prospective Longitudinal Cohort Study Type: Longitudinal dbGaP estimated ancestry using GRAF-pop Number of study subjects that have individual-level data available through Authorized Access: NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000285.v3.p2 on 2021-03-25 and may not include exact formatting or images.", - "Consent Code": "c1", - "Consent Short": "phs000285.v3.p2.c1", - "Subject Count": 3111 - }, - { - "Accession": "phs000285.v3.p2", - "Cohort Abbreviation": "CARDIA", - "Name": "Coronary Artery Risk Development in Young Adults (CARDIA) Study - Cohort", - "Description": "CARDIA is a study examining the etiology and natural history of cardiovascular disease beginning in young adulthood. In 1985-1986, a cohort of 5115 healthy black and white men and women aged 18-30 years were selected to have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, and education (high school or less and more than high school) within each of four US Field Centers. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), and 2010-2011 (Year 25); the proportions of the surviving cohort that have returned for the seven follow-up examinations were 90%, 86%, 81%, 79%, 74%, 72%, and 72%, respectively. In addition to the follow-up examinations, participants are contacted regularly for the ascertainment of information on out-patient procedures and hospitalizations experienced between contacts. Within the past five years, 95% of the original surviving cohort has been contacted. While the specifics of each examination has differed somewhat, data have been collected on a variety of factors believed to be related to heart disease. These include conditions with clear links to heart disease such as blood pressure, cholesterol and other lipids. Data have also been collected on physical measurements such as weight and skinfold fat as well as lifestyle factors such as substance use (tobacco and alcohol), dietary and exercise patterns, behavioral and psychological variables, medical and family history, and other chemistries (e.g., insulin and glucose). In addition, subclinical atherosclerosis was measured via echocardiography during Years 5, 10, and 25, computed tomography during Years 15 and 20, and carotid ultrasound during Year 20. The CARDIA Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the \"Sub-studies\" box located on the right hand side of this top-level study page phs000285 CARDIA Cohort. phs000236 PAGE_CALiCo_CARDIA phs000309 GENEVA_CARDIA phs000399 GO-ESP HeartGO_CARDIA phs000613 CARDIA_CARe Study Weblinks: CARDIA Study Design: Prospective Longitudinal Cohort Study Type: Longitudinal dbGaP estimated ancestry using GRAF-pop Number of study subjects that have individual-level data available through Authorized Access: NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000285.v3.p2 on 2021-03-25 and may not include exact formatting or images.", - "Consent Code": "c2", - "Consent Short": "phs000285.v3.p2.c2", - "Subject Count": 511 - }, { "Accession": "phs000286.v6.p2", "Cohort Abbreviation": "JHS", @@ -708,7 +690,7 @@ "Description": "This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, \"TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4\" and \"TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4\". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Participants from the Cardiovascular Health Study (CHS), a large population-based longitudinal cohort study (phs000287), have been included in the TOPMed project. Whole genome sequencing will be performed to contribute to multiple analyses, including cardiovascular disease risk factors, subclinical disease measures, the occurrence of myocardial infarction (MI) and stroke, and analyses of venous thromboembolism (VTE). Study Weblinks: CHS-NHLBI Study Design: Prospective Longitudinal Cohort Study Type:Longitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images.", "Consent Code": "c1", "Consent Short": "phs001368.v3.p2.c1", - "Subject Count": 3432 + "Subject Count": 4737 }, { "Accession": "phs001368.v3.p2", @@ -717,7 +699,7 @@ "Description": "This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, \"TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4\" and \"TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4\". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Participants from the Cardiovascular Health Study (CHS), a large population-based longitudinal cohort study (phs000287), have been included in the TOPMed project. Whole genome sequencing will be performed to contribute to multiple analyses, including cardiovascular disease risk factors, subclinical disease measures, the occurrence of myocardial infarction (MI) and stroke, and analyses of venous thromboembolism (VTE). Study Weblinks: CHS-NHLBI Study Design: Prospective Longitudinal Cohort Study Type:Longitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images.", "Consent Code": "c2", "Consent Short": "phs001368.v3.p2.c2", - "Subject Count": 121 + "Subject Count": 130 }, { "Accession": "phs001368.v3.p2", @@ -789,7 +771,7 @@ "Description": "This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, \"TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4\" and \"TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4\". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Comprehensive phenotypic and pedigree data for MESA study participants are available through dbGaP entry phs000209. MESA Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by five examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality. MESA Family The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia. In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping. The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study. Study Weblinks: MESA Study Design: Prospective Longitudinal Cohort Study Type:FamilyLongitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images.", "Consent Code": "c1", "Consent Short": "phs001416.v3.p1.c1", - "Subject Count": 4879 + "Subject Count": 7058 }, { "Accession": "phs001416.v3.p1", @@ -798,7 +780,7 @@ "Description": "This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, \"TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4\" and \"TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4\". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Comprehensive phenotypic and pedigree data for MESA study participants are available through dbGaP entry phs000209. MESA Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by five examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality. MESA Family The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia. In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping. The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study. Study Weblinks: MESA Study Design: Prospective Longitudinal Cohort Study Type:FamilyLongitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images.", "Consent Code": "c2", "Consent Short": "phs001416.v3.p1.c2", - "Subject Count": 499 + "Subject Count": 820 }, { "Accession": "phs001434.v1.p1", @@ -1367,6 +1349,24 @@ "Consent Short": "phs003212.v1.p1.c1", "Subject Count": 10 }, + { + "Accession": "phs003288.v1.p1", + "Cohort Abbreviation": "BL_MESA_HMB", + "Name": "Multi-Ethnic Study of Atherosclerosis (BioLINCC)", + "Description": "The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.Data available for request include data from exam 1 through exam 5 and events data updated through calendar year 2015. Also included are data from eleven ancillary studies: #079 (NT-ProBNP and Troponin), #042 (Epidemiology of Vascular Inflammation and Atherosclerosis), #081 (Apolipoproteins B and A-1), #067 (MRI RV-Function), #057 (Cystatin-C), #244 (NT Pro-BNP and HS Cardiac Troponin-T), #205 (Brachial IMT), #113 (Exam 5 Sleep), #047/075 (Vitamin D), #195 (Fatty Acid), #200 (Total FFA), #324 (Lipoprotein A), #023 (Neighborhood Racial Segregation), and #118 (Stress Cortisol).", + "Consent Code": "c1", + "Consent Short": "phs003288.v1.p1.c1", + "Subject Count": 6814 + }, + { + "Accession": "phs003288.v1.p1", + "Cohort Abbreviation": "BL_MESA_HMB-NPU", + "Name": "Multi-Ethnic Study of Atherosclerosis (BioLINCC)", + "Description": "The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.Data available for request include data from exam 1 through exam 5 and events data updated through calendar year 2015. Also included are data from eleven ancillary studies: #079 (NT-ProBNP and Troponin), #042 (Epidemiology of Vascular Inflammation and Atherosclerosis), #081 (Apolipoproteins B and A-1), #067 (MRI RV-Function), #057 (Cystatin-C), #244 (NT Pro-BNP and HS Cardiac Troponin-T), #205 (Brachial IMT), #113 (Exam 5 Sleep), #047/075 (Vitamin D), #195 (Fatty Acid), #200 (Total FFA), #324 (Lipoprotein A), #023 (Neighborhood Racial Segregation), and #118 (Stress Cortisol).", + "Consent Code": "c2", + "Consent Short": "phs003288.v1.p1.c2", + "Subject Count": 6043 + }, { "Accession": "", "Cohort Abbreviation": "", @@ -1430,6 +1430,15 @@ "Consent Short": "tutorial-biolincc_framingham", "Subject Count": 4434 }, + { + "Accession": "", + "Cohort Abbreviation": "RECOVER_synthetic_data_set_1", + "Name": "Researching COVID to Enhance Recovery (RECOVER) - Synthetic Dataset", + "Description": "The National Institutes of Health (NIH) created the RECOVER Initiative to learn about the long-term effects of COVID. The goal of RECOVER is to rapidly improve our understanding of and ability to predict, treat, and prevent PASC (post-acute sequelae of SARS-CoV-2), including Long COVID.", + "Consent Code": "", + "Consent Short": "RECOVER_synthetic_data_set_1", + "Subject Count": 92 + }, { "Accession": "", "Cohort Abbreviation": "", From c29fb96ce27a4edbf6b2afca998d34c162e122f3 Mon Sep 17 00:00:00 2001 From: suejinkim20 Date: Fri, 3 Nov 2023 11:47:41 -0400 Subject: [PATCH 2/4] open pic-sure link opens in a new tab --- src/data/platforms/pic-sure.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/src/data/platforms/pic-sure.md b/src/data/platforms/pic-sure.md index 1d9d9dbb..96a6ae6e 100644 --- a/src/data/platforms/pic-sure.md +++ b/src/data/platforms/pic-sure.md @@ -10,7 +10,7 @@ links: launch: https://picsure.biodatacatalyst.nhlbi.nih.gov documentation: https://bdcatalyst.gitbook.io/biodata-catalyst-documentation/explore_data/pic-sure-for-biodata-catalyst-user-guide about: The Patient Information Commons Standard Unification of Research Elements (PIC-SURE) user interface gives investigators the ability to search available data and conduct feasibility queries, allowing for cohorts to be built in real-time and results to be exported via the PIC-SURE API for analysis. -service: Explore available data through BDC-PIC-SURE with interactive search and visualizations for feasibility assessment. Use query results to create a cohort, with the ability to choose specific variables of interest to export into an analysis environment.

Launch Open PIC-SURE (eRA login not required)*
*Open PIC-SURE does not export data to analysis environments. +service: Explore available data through BDC-PIC-SURE with interactive search and visualizations for feasibility assessment. Use query results to create a cohort, with the ability to choose specific variables of interest to export into an analysis environment.

Launch Open PIC-SURE (eRA login not required)*
*Open PIC-SURE does not export data to analysis environments. --- - Search ALL phenotypic data by typing terms directly in the search bar to find variables of interest across all available studies From a4a52a1a345c31eb10165b25444229a1f65210ef Mon Sep 17 00:00:00 2001 From: suejinkim20 Date: Fri, 3 Nov 2023 12:28:41 -0400 Subject: [PATCH 3/4] add rel attribute to open pic-sure link --- src/data/platforms/pic-sure.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/src/data/platforms/pic-sure.md b/src/data/platforms/pic-sure.md index 96a6ae6e..0ce9a047 100644 --- a/src/data/platforms/pic-sure.md +++ b/src/data/platforms/pic-sure.md @@ -10,7 +10,7 @@ links: launch: https://picsure.biodatacatalyst.nhlbi.nih.gov documentation: https://bdcatalyst.gitbook.io/biodata-catalyst-documentation/explore_data/pic-sure-for-biodata-catalyst-user-guide about: The Patient Information Commons Standard Unification of Research Elements (PIC-SURE) user interface gives investigators the ability to search available data and conduct feasibility queries, allowing for cohorts to be built in real-time and results to be exported via the PIC-SURE API for analysis. -service: Explore available data through BDC-PIC-SURE with interactive search and visualizations for feasibility assessment. Use query results to create a cohort, with the ability to choose specific variables of interest to export into an analysis environment.

Launch Open PIC-SURE (eRA login not required)*
*Open PIC-SURE does not export data to analysis environments. +service: Explore available data through BDC-PIC-SURE with interactive search and visualizations for feasibility assessment. Use query results to create a cohort, with the ability to choose specific variables of interest to export into an analysis environment.

Launch Open PIC-SURE (eRA login not required)*
*Open PIC-SURE does not export data to analysis environments. --- - Search ALL phenotypic data by typing terms directly in the search bar to find variables of interest across all available studies From 48ca9b757450e6f342079ab8c516884eaeeaab0e Mon Sep 17 00:00:00 2001 From: Matt Watson Date: Fri, 3 Nov 2023 12:31:17 -0400 Subject: [PATCH 4/4] Revert "Merge pull request #398 from stagecc/update-studies-2023-10-16-05.15.59AM" This reverts commit 184f2cd47f4454ebae7e1099c4cb1c7b9cc48c1a, reversing changes made to 69acf8530b09fd9ac83dada12ba2ffc1fc4987d4. --- src/data/studies/studies.json | 53 +++++++++++++++-------------------- 1 file changed, 22 insertions(+), 31 deletions(-) diff --git a/src/data/studies/studies.json b/src/data/studies/studies.json index b5d88772..d6802edf 100644 --- a/src/data/studies/studies.json +++ b/src/data/studies/studies.json @@ -98,6 +98,24 @@ "Consent Short": "phs000284.v2.p1.c1", "Subject Count": 1473 }, + { + "Accession": "phs000285.v3.p2", + "Cohort Abbreviation": "CARDIA", + "Name": "Coronary Artery Risk Development in Young Adults (CARDIA) Study - Cohort", + "Description": "CARDIA is a study examining the etiology and natural history of cardiovascular disease beginning in young adulthood. In 1985-1986, a cohort of 5115 healthy black and white men and women aged 18-30 years were selected to have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, and education (high school or less and more than high school) within each of four US Field Centers. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), and 2010-2011 (Year 25); the proportions of the surviving cohort that have returned for the seven follow-up examinations were 90%, 86%, 81%, 79%, 74%, 72%, and 72%, respectively. In addition to the follow-up examinations, participants are contacted regularly for the ascertainment of information on out-patient procedures and hospitalizations experienced between contacts. Within the past five years, 95% of the original surviving cohort has been contacted. While the specifics of each examination has differed somewhat, data have been collected on a variety of factors believed to be related to heart disease. These include conditions with clear links to heart disease such as blood pressure, cholesterol and other lipids. Data have also been collected on physical measurements such as weight and skinfold fat as well as lifestyle factors such as substance use (tobacco and alcohol), dietary and exercise patterns, behavioral and psychological variables, medical and family history, and other chemistries (e.g., insulin and glucose). In addition, subclinical atherosclerosis was measured via echocardiography during Years 5, 10, and 25, computed tomography during Years 15 and 20, and carotid ultrasound during Year 20. The CARDIA Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the \"Sub-studies\" box located on the right hand side of this top-level study page phs000285 CARDIA Cohort. phs000236 PAGE_CALiCo_CARDIA phs000309 GENEVA_CARDIA phs000399 GO-ESP HeartGO_CARDIA phs000613 CARDIA_CARe Study Weblinks: CARDIA Study Design: Prospective Longitudinal Cohort Study Type: Longitudinal dbGaP estimated ancestry using GRAF-pop Number of study subjects that have individual-level data available through Authorized Access: NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000285.v3.p2 on 2021-03-25 and may not include exact formatting or images.", + "Consent Code": "c1", + "Consent Short": "phs000285.v3.p2.c1", + "Subject Count": 3111 + }, + { + "Accession": "phs000285.v3.p2", + "Cohort Abbreviation": "CARDIA", + "Name": "Coronary Artery Risk Development in Young Adults (CARDIA) Study - Cohort", + "Description": "CARDIA is a study examining the etiology and natural history of cardiovascular disease beginning in young adulthood. In 1985-1986, a cohort of 5115 healthy black and white men and women aged 18-30 years were selected to have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, and education (high school or less and more than high school) within each of four US Field Centers. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), and 2010-2011 (Year 25); the proportions of the surviving cohort that have returned for the seven follow-up examinations were 90%, 86%, 81%, 79%, 74%, 72%, and 72%, respectively. In addition to the follow-up examinations, participants are contacted regularly for the ascertainment of information on out-patient procedures and hospitalizations experienced between contacts. Within the past five years, 95% of the original surviving cohort has been contacted. While the specifics of each examination has differed somewhat, data have been collected on a variety of factors believed to be related to heart disease. These include conditions with clear links to heart disease such as blood pressure, cholesterol and other lipids. Data have also been collected on physical measurements such as weight and skinfold fat as well as lifestyle factors such as substance use (tobacco and alcohol), dietary and exercise patterns, behavioral and psychological variables, medical and family history, and other chemistries (e.g., insulin and glucose). In addition, subclinical atherosclerosis was measured via echocardiography during Years 5, 10, and 25, computed tomography during Years 15 and 20, and carotid ultrasound during Year 20. The CARDIA Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the \"Sub-studies\" box located on the right hand side of this top-level study page phs000285 CARDIA Cohort. phs000236 PAGE_CALiCo_CARDIA phs000309 GENEVA_CARDIA phs000399 GO-ESP HeartGO_CARDIA phs000613 CARDIA_CARe Study Weblinks: CARDIA Study Design: Prospective Longitudinal Cohort Study Type: Longitudinal dbGaP estimated ancestry using GRAF-pop Number of study subjects that have individual-level data available through Authorized Access: NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000285.v3.p2 on 2021-03-25 and may not include exact formatting or images.", + "Consent Code": "c2", + "Consent Short": "phs000285.v3.p2.c2", + "Subject Count": 511 + }, { "Accession": "phs000286.v6.p2", "Cohort Abbreviation": "JHS", @@ -690,7 +708,7 @@ "Description": "This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, \"TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4\" and \"TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4\". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Participants from the Cardiovascular Health Study (CHS), a large population-based longitudinal cohort study (phs000287), have been included in the TOPMed project. Whole genome sequencing will be performed to contribute to multiple analyses, including cardiovascular disease risk factors, subclinical disease measures, the occurrence of myocardial infarction (MI) and stroke, and analyses of venous thromboembolism (VTE). Study Weblinks: CHS-NHLBI Study Design: Prospective Longitudinal Cohort Study Type:Longitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images.", "Consent Code": "c1", "Consent Short": "phs001368.v3.p2.c1", - "Subject Count": 4737 + "Subject Count": 3432 }, { "Accession": "phs001368.v3.p2", @@ -699,7 +717,7 @@ "Description": "This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, \"TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4\" and \"TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4\". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Participants from the Cardiovascular Health Study (CHS), a large population-based longitudinal cohort study (phs000287), have been included in the TOPMed project. Whole genome sequencing will be performed to contribute to multiple analyses, including cardiovascular disease risk factors, subclinical disease measures, the occurrence of myocardial infarction (MI) and stroke, and analyses of venous thromboembolism (VTE). Study Weblinks: CHS-NHLBI Study Design: Prospective Longitudinal Cohort Study Type:Longitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images.", "Consent Code": "c2", "Consent Short": "phs001368.v3.p2.c2", - "Subject Count": 130 + "Subject Count": 121 }, { "Accession": "phs001368.v3.p2", @@ -771,7 +789,7 @@ "Description": "This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, \"TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4\" and \"TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4\". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Comprehensive phenotypic and pedigree data for MESA study participants are available through dbGaP entry phs000209. MESA Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by five examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality. MESA Family The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia. In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping. The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study. Study Weblinks: MESA Study Design: Prospective Longitudinal Cohort Study Type:FamilyLongitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images.", "Consent Code": "c1", "Consent Short": "phs001416.v3.p1.c1", - "Subject Count": 7058 + "Subject Count": 4879 }, { "Accession": "phs001416.v3.p1", @@ -780,7 +798,7 @@ "Description": "This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, \"TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4\" and \"TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4\". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Comprehensive phenotypic and pedigree data for MESA study participants are available through dbGaP entry phs000209. MESA Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by five examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality. MESA Family The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia. In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping. The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study. Study Weblinks: MESA Study Design: Prospective Longitudinal Cohort Study Type:FamilyLongitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images.", "Consent Code": "c2", "Consent Short": "phs001416.v3.p1.c2", - "Subject Count": 820 + "Subject Count": 499 }, { "Accession": "phs001434.v1.p1", @@ -1349,24 +1367,6 @@ "Consent Short": "phs003212.v1.p1.c1", "Subject Count": 10 }, - { - "Accession": "phs003288.v1.p1", - "Cohort Abbreviation": "BL_MESA_HMB", - "Name": "Multi-Ethnic Study of Atherosclerosis (BioLINCC)", - "Description": "The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.Data available for request include data from exam 1 through exam 5 and events data updated through calendar year 2015. Also included are data from eleven ancillary studies: #079 (NT-ProBNP and Troponin), #042 (Epidemiology of Vascular Inflammation and Atherosclerosis), #081 (Apolipoproteins B and A-1), #067 (MRI RV-Function), #057 (Cystatin-C), #244 (NT Pro-BNP and HS Cardiac Troponin-T), #205 (Brachial IMT), #113 (Exam 5 Sleep), #047/075 (Vitamin D), #195 (Fatty Acid), #200 (Total FFA), #324 (Lipoprotein A), #023 (Neighborhood Racial Segregation), and #118 (Stress Cortisol).", - "Consent Code": "c1", - "Consent Short": "phs003288.v1.p1.c1", - "Subject Count": 6814 - }, - { - "Accession": "phs003288.v1.p1", - "Cohort Abbreviation": "BL_MESA_HMB-NPU", - "Name": "Multi-Ethnic Study of Atherosclerosis (BioLINCC)", - "Description": "The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.Data available for request include data from exam 1 through exam 5 and events data updated through calendar year 2015. Also included are data from eleven ancillary studies: #079 (NT-ProBNP and Troponin), #042 (Epidemiology of Vascular Inflammation and Atherosclerosis), #081 (Apolipoproteins B and A-1), #067 (MRI RV-Function), #057 (Cystatin-C), #244 (NT Pro-BNP and HS Cardiac Troponin-T), #205 (Brachial IMT), #113 (Exam 5 Sleep), #047/075 (Vitamin D), #195 (Fatty Acid), #200 (Total FFA), #324 (Lipoprotein A), #023 (Neighborhood Racial Segregation), and #118 (Stress Cortisol).", - "Consent Code": "c2", - "Consent Short": "phs003288.v1.p1.c2", - "Subject Count": 6043 - }, { "Accession": "", "Cohort Abbreviation": "", @@ -1430,15 +1430,6 @@ "Consent Short": "tutorial-biolincc_framingham", "Subject Count": 4434 }, - { - "Accession": "", - "Cohort Abbreviation": "RECOVER_synthetic_data_set_1", - "Name": "Researching COVID to Enhance Recovery (RECOVER) - Synthetic Dataset", - "Description": "The National Institutes of Health (NIH) created the RECOVER Initiative to learn about the long-term effects of COVID. The goal of RECOVER is to rapidly improve our understanding of and ability to predict, treat, and prevent PASC (post-acute sequelae of SARS-CoV-2), including Long COVID.", - "Consent Code": "", - "Consent Short": "RECOVER_synthetic_data_set_1", - "Subject Count": 92 - }, { "Accession": "", "Cohort Abbreviation": "",